Non-linear Compartmental Model for Patient-Specific Antibody Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current dosing models for monoclonal antibodies in cancer treatment are not patient-specific, leading to suboptimal therapeutic outcomes due to the saturability of antibody-antigen interactions, requiring a more nuanced approach for individualized tumor targeting.
Innovation Solution
A non-linear compartmental modeling approach using PET-derived data to determine best-fit parameters for optimizing the biodistribution of intravenously injected anti-tumor antibodies, allowing for patient-specific determination of optimal therapeutic doses and dosing schedules, applicable to antibodies like A33, hu11B6, and J591.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If linear dosing models are used for monoclonal antibodies, then dosing is simplified and can be applied universally, but the saturability of antibody-antigen interactions is not accounted for, leading to suboptimal therapeutic outcomes
Solution Approach 1:
The patent transitions from linear dosing models to non-linear compartmental modeling that accounts for the saturability of antibody-antigen interactions. This involves changing the mathematical parameters from simple linear relationships to complex non-linear differential equations that model the actual biological saturation kinetics, thereby improving therapeutic outcomes while maintaining computational feasibility through automated fitting procedures
Solution Approach 2:
The patent performs preliminary PET imaging and kinetic parameter estimation before final dose determination. By conducting pre-therapy imaging to measure antigen expression levels and kinetic parameters, the system prepares patient-specific parameters in advance that guide the subsequent dosing calculation, enabling personalized dosing without requiring complex real-time adjustments during treatment
2Ease of manufacture
If current empirical dosing methods are used, then dose determination is straightforward, but laborious and time-consuming dose-escalation studies are required to optimize dosing
Solution Approach 1:
The patent implements a feedback loop where PET imaging data from individual patients is used to measure actual antibody kinetics and antigen expression, which then feeds into the non-linear compartmental model to calculate personalized optimal doses. This feedback mechanism replaces time-consuming empirical dose-escalation studies with direct patient-specific measurements, significantly reducing the time required for dose optimization
Solution Approach 2:
The patent replaces the mechanical/empirical approach of dose-escalation studies with a computational modeling approach based on PET imaging and non-linear kinetic analysis. By substituting biological trial-and-error methods with mathematical modeling and imaging-based measurements, the system achieves dose optimization without requiring laborious clinical studies
3Adaptability or versatility
If non-linear compartmental modeling with PET imaging is implemented, then patient-specific optimal doses can be determined, but the complexity of the dosing model increases
Solution Approach 1:
The patent develops a universal non-linear compartmental modeling framework that can be applied to different monoclonal antibodies and cancer types through PET imaging. The same mathematical model structure and fitting procedures can accommodate various antibodies by adjusting kinetic parameters, providing a versatile multi-functional solution that handles patient-specific variability without requiring separate models for each antibody or cancer type
Solution Approach 2:
The patent introduces PET imaging as an intermediary that bridges the gap between complex biological variability and simplified dosing calculations. The imaging data serves as a measurable proxy for antigen expression and antibody kinetics, allowing the complex non-linear model to be constrained and solved using observable parameters, thereby managing model complexity while maintaining patient-specific accuracy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables personalized optimization of antibody doses, improving tumor targeting efficiency and reducing off-target uptake, thereby enhancing the therapeutic index and minimizing toxicity.
Implementation Method 1
the uptake and kinetics of an 124I-labeled humanized anti-A33 mAb, huA33, in tumor and normal-tissue of colorectal cancer patients using positron emission tomography (PET)
Implementation Method 2
PET imaging can accurately and non-invasively quantitate the time-dependent antibody concentrations in vivo
Data Source
AI summary
The present disclosure describes a non-linear compartmental model using PET-derived data to predict, on a patient-specific basis, the optimal therapeutic dose of cargo carrying antibody (e.g., huA33) such as radiolabeled antibody, the antigen occupancy, residency times in normal and malignant tissues, and the cancer-to-normal tissue (e.g., colorectal cancer-to-normal colon tissue) therapeutic index. In addition, the non-linear compartmental model can be readily applied to the development of strategies such as multi-step targeting (MST) designed to further improve the therapeutic indices of RIT.